Rezolute, Inc. - FORM 8-K - EX-99.3 - UNAUDITED PRO FORMA FINANCIAL STATEMENTS AND RELATED NOTES THERETO - February 5, 2013

Attached files

file filename
EX-10.5 - ADVISORY SERVICES AGREEMENT WITH KONUS ADVISORY GROUP. INC., DATED JULY 2, 2012 - Rezolute, Inc.ex10_5.htm
EX-10.6 - CONSULTING AGREEMENT WITH HOYOUNG HUH, DATED JULY 1, 2012 - Rezolute, Inc.ex10_6.htm
EX-10.1 - ASSET PURCHASE AGREEMENT WITH PR PHARMACEUTICALS, INC. - Rezolute, Inc.ex10_1.htm
EX-10.2 - EMPLOYMENT AGREEMENT WITH STEVE HOWE, DATED APRIL 1, 2012 - Rezolute, Inc.ex10_2.htm
EX-99.1 - AUDITED BALANCE SHEETS OF ANTRIABIO DELAWARE, INC. (FORMERLY KNOWN AS ANTRIABIO, INC.) AS OF DECEMBER 31, 2011 AND 2010 AND THE RELATED STATEMENTS OF COMPREHENSIVE LOSS, STOCKHOLDERS? EQUITY (DEFICIT) AND CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2011 AN - Rezolute, Inc.ex99_1.htm
EX-10.9 - OPTION AGREEMENT WITH SANKARAM MANTRIPRAGADA, DATED JANUARY __, 2013 - Rezolute, Inc.ex10_9.htm
EX-10.4 - EMPLOYMENT AGREEMENT WITH SANKARAM MANTRIPRAGADA, DATED APRIL 1, 2012 - Rezolute, Inc.ex10_4.htm
8-K - Rezolute, Inc.antriabio_8k-02042013.htm
EX-10.3 - EMPLOYMENT AGREEMENT WITH NEVAN ELAM, DATED JUNE 18, 2012 - Rezolute, Inc.ex10_3.htm
EX-2.1 - SHARE EXCHANGE AND REORGANIZATION AGREEMENT, JANUARY 14, 2013 - Rezolute, Inc.ex2_1.htm
EX-99.4 - PRESS RELEASE DATED JANUARY 31, 2013 - Rezolute, Inc.ex99_4.htm
EX-10.7 - OPTION AGREEMENT WITH STEVE HOWE, DATED JANUARY __, 2013 - Rezolute, Inc.ex10_7.htm
EX-23.1 - SPECTRA CONSENT - Rezolute, Inc.ex23_1.htm
EX-99.2 - UNAUDITED BALANCE SHEET OF ANTRIABIO DELAWARE, INC. (FORMERLY KNOWN AS ANTRIABIO, INC.) AS OF SEPTEMBER 30, 2012 AND THE RELATED STATEMENTS OF COMPREHENSIVE LOSS, SHAREHOLDERS? EQUITY (DEFICIT) AND CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012 A - Rezolute, Inc.ex99_2.htm
EX-10.8 - OPTION AGREEMENT WITH NEVAN ELAM, DATED JANUARY __, 2013 - Rezolute, Inc.ex10_8.htm
EX-10.10 - OPTION AGREEMENT WITH HOYOUNG HUH, DATED JANUARY __, 2013 - Rezolute, Inc.ex10_10.htm
EXHIBIT 99.3
 
PROFORMA COMBINED FINANCIAL STATEMENTS
 
On January 30, 2013, AntriaBio, Inc. (the “Company”) entered into a share exchange and reorganization agreement (the “Share Exchange and Reorganization Agreement”) dated January 14, 2013, by and among the Company, AntriaBio Delaware, Inc., a Delaware corporation (“AntriaBio Delaware”), and the beneficial stockholders of AntriaBio Delaware (the “AntriaBio Stockholders”), pursuant to which the AntriBio Stockholders agreed to exchange all of the outstanding capital stock AntriaBio Delaware (the “AntriaBio Capital Stock”) for an aggregate of 35,284,000 shares of the  Company’s common stock representing approximately 88% of the Company’s issued and outstanding capital stock giving effect to such issuance and the other transactions described herein.  As a result of such transaction, AntriaBio Delaware shall become a wholly-owned subsidiary of the Company.  In connection with the Share Exchange and Reorganization Agreement, Tungsten 74, LLC, the majority stockholder of the Company agreed to deliver to the Company for cancellation its 19,890,000 shares of the Company’s common stock (collectively we refer to these transactions as the “Reverse Merger”),

The unaudited pro forma combined financial statements presented below are prepared using recapitalization accounting for the Reverse Merger. Pro forma adjustments which give effect to certain transactions occurring as a direct result of the Reverse Merger are described in the accompanying unaudited notes presented on the following pages.

The unaudited pro forma combined balance sheet is prepared as though the Reverse Merger occurred at the close of business on September 30, 2012.  The unaudited pro forma combined statements of comprehensive loss give effect to the Reverse Merger as though it occurred on July 1, 2011.  The Company’s fiscal year end is June 30. AntriaBio Delaware’s fiscal year end is December 31. The statements of of comprehensive loss for AntriaBio Delaware are presented for the three months ended September 30, 2012, and for the year ended June 30, 2012 to conform to the Company’s fiscal year end of June 30.

The unaudited pro forma combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the consolidated financial position or results of operations in future periods or the results that actually would have been realized had the Company and AntriaBio Delaware been a combined company during the specified periods. The unaudited pro forma combined financial statements, including the notes thereto, are qualified in their entirety by reference to, and should be read in conjunction with, the historical financial statements of AntriaBio Delaware included herein and the historical financial statements of the Company included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2012 as filed with the United States Securities and Exchange Commission (“SEC”) on November 5, 2012 and in its Quarterly Report on Form 10-Q for the three months ended September 30, 2012 as filed with the SEC on November 19, 2012.
 

1
 
 

AntriaBio, Inc.
Pro Forma Combined Balance Sheet
(Unaudited)


 
AntriaBio
                    
Pro Forma
  
 
Delaware, Inc.
    
AntriaBio, Inc
              
Combined
  
 
September 30,
    
September 30,
    
Pro Forma
        
September 30,
  
                 Assets
2012
    
2012
    
Adjustments
  
Adj #
    
2012
  
                           
Current assets
                          
Cash and cash equivalents
 $ 291,684     $ 480     $ (300,000 )   A     $ (7,836 )
Note receivable - related party, net
   915,826       -       -             915,826  
Interest receivable - related party
   12,330       -       -             12,330  
Other current assets
   209,063       -       (100,000 )   A        109,063  
Total current assets
   1,428,903       480       (400,000 )           1,029,383  
                                     
Long-Term Assets, Assets acquired
   -       -       400,000     A        400,000  
Total assets
 $ 1,428,903     $ 480     $ -           $ 1,429,383  
                                     
Liabilities and Shareholders' Equity (Deficit)
                                    
                                     
Current liabilities
                                    
Accrued expenses
 $ 287,935     $ 15,643     $ -           $ 303.578  
Convertible notes payable
   2,898,767       -       -             2,898,767  
Due to related parties
   2,140       -       -             2,140  
Interest payable
   159,824       -       -             159,824  
Total current liabilities
   3,348,666       15,643       -             3,364,309  
                                     
Total liabilities
   3,348,666       15,643       -             3,364,309  
                                     
Commitments and Contingencies (Note 10)
                                    
                                     
Shareholders' equity (deficit)
                                    
Common stock
   353       4,101       35,546     B, C       40,000  
Common stock, subscribed
   (353 )     -       353     C        -  
Additional paid in capital
   100       81,699       (35,899 )   B, C       45,900  
Deficit accumulated during the development stage
   (1,919,863 )     (100,963 )     -             (2,020,826 )
Total shareholders' equity (deficit)
   (1,919,763 )     (15,163 )     -             (1,934,926 )
                                     
Total liabilities and shareholders' equity (deficit)
 $ 1,428,903     $ 480     $ -           $ 1,429,383  

 
2
 
 

AntriaBio, Inc.
Pro Forma Combined Statement of Comprehensive Loss
For three months ended September 30, 2012
(Unaudited)
 
   
AntriaBio
    
Pro Forma
  
Pro Forma
  
   
Delaware, Inc.
  
AntriaBio, Inc.
    
Adjustments
  
Adj #
  
Combined
  
                           
Revenue
                          
Sales
   $ -     $ -     $ -       $ -  
Total revenue
     -       -       -         -  
                                   
Operating expenses
                                  
Consulting fees
     117,641       -       -         117,641  
Insurance
     4,241       -       -         4,241  
Meals and entertainment
     1,642       -       -         1,642  
Payroll
     200,567       -       -         200,567  
Professional fees
     154,408       -       -         154,408  
Rent
     15,792       -       -         15,792  
Travel
     43,581       -       -         43,581  
General and administrative
     5,011       9,749       -         14,760  
Total operating expenses
     542,883       9,749       -         552,632  
                                   
Loss from operations
     (542,883 )     (9,749 )     -         (552,632 )
                                   
Other income (expense)
                            
Interest income
     16,930       -       -         16,930  
Interest expense
     (104,898 )     -       -         (104,898 )
Total other income (expense)
     (87,968 )     -       -         (87,968 )
                                   
Loss before income taxes
     (630,851 )     (9,749 )     -         (640,600 )
                                   
Income tax expense
     -       -       -         -  
                                   
Net loss
     (630,851 )     (9,749 )     -         (640,600 )
                                   
Other comprehensive income (loss)
     -       -       -         -  
                                   
Total comprehensive loss
   $ (630,851 )   $ (9,749 )   $ -       $ (640,600 )
                                   
                                   
Loss per common share - basic and diluted
   $ (0.02 )   $ (0.00 )   $ -       $ (0.002 )
                                   
Weighted average common shares
                    
outstanding - basic and diluted
     35,284,000       4,101,000       615,000  
 D
     40,000,000  

 
 
3
 
 
 
AntriaBio, Inc.
Pro Forma Combined Income Statement of Comprehensive Loss
For twelve months ended June 30, 2012
(Unaudited)
 
 
   
AntriaBio
    
Pro Forma
    
Pro Forma
  
   
Delaware, Inc.
  
AntriaBio, Inc.
    
Adjustments
    
Adj #
  
Combined
  
                               
Revenue
                              
Sales
   $ -     $ -     $ -           $ -  
Total revenue
     -       -       -             -  
                                       
Operating expenses
                                      
Consulting fees
     33,500       -       -             33,500  
Insurance
     17,594       -       -             17,594  
Meals and entertainment
     8,188       -       -             8,188  
Payroll
     150,813       -       -             150,813  
Professional fees
     95,612       -       -             95,612  
Rent
     55,196       -       -             55,196  
Repair and maintenance
     5,758       -       -             5,758  
Travel
     116,825       -       -             116,825  
Loss on impairment
     -       1,779       (1,779 )       E     -  
General and administrative
     6,350       47,508       (47,508 )       E     6,350  
Total expenses
     489,836       49,287       (49,287 )             489,836  
                                         
Loss from operations
     (489,836 )     (49,287 )     49,287               (489,836 )
                                         
Other income (expense)
                                  
Interest income
     31,547       -       -               31,547  
Interest expense
     (325,094 )     -       -               (325,094 )
Total other income (expense)
     (293,547 )     -       -               (293,547 )
                                         
Loss before income taxes
     (783,383 )     (49,287 )     49,287               (783,383 )
                                         
Income tax expense
     -       -       -               -  
                                         
Net loss
     (783,383 )     (49,287 )     49,287               (783,383 )
                                         
Other comprehensive income (loss)
     -       -       -               -  
                                         
Total comprehensive loss
   $ (783,383 )     (49,287 )   $ 49,287             $ (783,383 )
                                         
                                         
Loss per common share - basic and diluted
   $ (0.02 )   $ (0.01 )   $ (0.09 )           $ (0.02 )
                                         
Weighted average common shares
                          
outstanding - basic and diluted
     35,284,000       3,867,637       (551,815 )       D     38,599,822  


4
 
 

AntriaBio, Inc.
Notes and Assumptions to Pro Forma Combined Financial Statements
 (Unaudited)


 
(A)
On October 5, 2012, subsequent to the historical balance sheet date presented and prior to the reverse merger, AntriaBio Delaware entered into an Asset Purchase Agreement for $400,000.   At the time of the reverse merger, the values of assets acquired were still being determined.
 
(B)
On January 10, 2013, AntriaBio, Inc.  completed a 6-for-1 stock split whereby each share of common stock was converted into 6 shares of common stock (leaving 24,606,000 common shares outstanding).
 
(C)
To adjust AntriaBio, Inc. shareholders’ equity (deficit) accounts to reflect the effects of the recapitalization, including, 4,716,000 shares of existing Company stock (net of 19,890,000 shares retired at date of reverse merger) and the conversion of all outstanding common shares of AntriaBio Delaware into 35,284,000 common shares of AntriaBio, Inc. at par value of $0.001.
 
(D)
To reflect the 6-for-1 stock split of the Company stock as well as the retirement of 19,890,000 shares related to the reverse merger.
 
(E)
These balances were adjusted as they relate to the previous business model of AntriaBio, Inc. which is no longer being conducted subsequent to the reverse merger and therefore were adjusted out of the balance.
 
The unaudited pro forma combined financial statements do not include any adjustment for non-recurring costs incurred or to be incurred after September 30, 2012 by both the Company and AntriaBio Delaware to consummate the Reverse Merger, except as noted above.  Merger costs include fees payable for legal and accounting fees.  Such costs will be expensed as incurred.
 

5
 
 

Rezolute, Inc. Reports